gastric inhibitory polypeptide

Gastric Inhibitory Polypeptide (1-30), porcine, deficient in the 12 C-terminal amino acids of the natural gastric inhibitory polypeptide (GIP), demonstrates biological activity by enhancing the release of insulin and somatostatin [1].

Gastric Inhibitory Polypeptide (6-30) amide (human) is an incretin hormone used in diabetes research [1].

This GIP fragment has potent insulinotropic activity in the isolated, perfused rat pancreas but greatly reduced somatostatinotropic activity in the isolated perfused rat stomach. The site responsible for insulinotropic activity apparently lies between residues 19 and 30 of GIP.

GIP (3-42), human (Gastric Inhibitory Polypeptide (3-42) (human)) is a peptide that acts as a glucose-dependent proinsulinotropic polypeptide (GIP) receptor antagonist and regulates insulin secretion and the metabolic effects of GIP in vivo, which can be used to study type 2 diabetes.

GIP (1-30) amide, porcine TFA is a high-affinity full agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor, with potency comparable to native GIP(1-42) [1]. It also exhibits potent insulin-stimulating properties and weakly inhibits gastric acid secretion.

[Tyr0] Gastric Inhibitory Peptide (23-42), human, is a glucose-dependent insulinotropic polypeptide (GIP) that modestly inhibits gastric acid secretion while enhancing insulin secretion, making it relevant for research on diabetes and obesity [1] [2].

Gastric Inhibitory Peptide (porcine), also known as a glucose-dependent insulinotropic polypeptide, is a 42-amino acid intestinal hormone that influences fat and glucose metabolism [1].

Acetyl Gastric Inhibitory Peptide (human), a fatty acid-derivatized analog of glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic characteristics. This compound is utilized in diabetes, insulin resistance, and obesity research [1] [2] [3].

Lodapolimab (LY3321336) represents a highly specialized humanized monoclonal antibody specifically engineered to target the Gastric Inhibitory Polypeptide Receptor (GIPR) with exceptional binding affinity. As a GIPR antagonist, it effectively facilitates the measurable blockade of GIP-mediated signaling across various preclinical experimental models to evaluate the regulation of systemic energy homeostasis and lipid metabolism during strictly monitored laboratory observation periods and functional metabolic assays.

Acetyl Gastric Inhibitory Peptide (human) TFA, a fatty acid-derivatized analog of the glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic properties. It is utilized in the research of diabetes, insulin resistance, and obesity [1] [2] [3].

Maridebart represents a highly specialized humanized monoclonal antibody specifically engineered to target the human growth differentiation factor 15 with exceptional binding affinity and selectivity, effectively facilitating the measurable neutralization of ligand-mediated signaling within the GFRAL receptor pathway to evaluate its functional role in systemic metabolic regulation and the prevention of cancer-associated cachexia during strictly monitored laboratory observation periods and functional appetite regulation assays to ensure high experimental sensitivity and accuracy.

GIP, rat TFA (glucose-dependent insulinotropic polypeptide), a 42-amino acid peptide secreted by K cells in the duodenum and jejunum, promotes insulin release from pancreatic beta cells, supports beta cell proliferation, and enhances their survival. This rat-origin bioactive peptide, along with GLP (gastric-like peptide), belongs to the intestinal insulinotropic hormone family and is implicated in lipid homeostasis and potentially in the pathogenesis of obesity. Recent research suggests GIP's multifaceted role in these metabolic processes.

GIP (rat) (Glucose-dependent Insulinotropic Polypeptide), also known as Gastric Inhibitory Polypeptide, is a biologically active 42-amino acid peptide secreted by the K cells of the duodenum and jejunum following food consumption. It belongs to the incretin hormone peptide family, which includes GLP (Gastric-like Peptide), and it not only stimulates insulin release from pancreatic islet β-cells but also may encourage β-cell proliferation and survival. Additionally, recent research indicates GIP may have a role in lipid regulation and could contribute to the development of obesity.

Gastric Inhibitory Peptide (1-42) (porcine) TFA is a glucose-dependent insulinotropic polypeptide released by intestinal K-cells. It stimulates insulin secretion while inhibiting gastric acid secretion and gastrointestinal motility, thereby regulating digestive function.

Efocipegtrutide is a potent agonist of glucagon, gastric inhibitory polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors, sharing balanced sequence homology with glucagon, GLP-1, and GIP (glucose-dependent insulinotropic polypeptide, incretin hormone) [1].

Taspoglutide, acting as an agonist for the glucagon-like peptide-1 receptor (GLP-1R; Ki = 1.1 nM for the human receptor), induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). In oral glucose tolerance tests conducted on Zucker diabetic fatty rats, Taspoglutide (administered weekly at 1 mg/animal) significantly reduced blood glucose levels and increased insulin levels. Additionally, in the same model, it also lowered blood levels of gastric inhibitory polypeptide (GIP), plasma triglycerides, and body weight.

Olatorepatide (Olatorepatidum) is a dual agonist for the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, exhibiting antidiabetic effects.

Macupatide is a gastric inhibitory polypeptide (GIP) receptor agonist, utilized in research related to antidiabetic applications.

Ribupatide is a dual agonist of gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptors and can be utilized in antidiabetic research.

Macupatide acetate is a gastric inhibitory polypeptide (GIP) receptor agonist that may be utilized in diabetes research.

Relsipatide (BG128) is a dual agonist of the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is utilized in antidiabetic research.